Trade Setup Buy Target $102.10 Sell Target $113.75 Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung […]
Read MorePlus, Raymond James analysts said China’s response to the virus outbreak is reminiscent of the Soviet Union’s reaction to the Chernobyl nuclear accident, Walmart missed on earnings, and Franklin Resources is buying rival Legg Mason.
Read MoreBuy Target – $9.25 or better Sell Target – TradersPro Sell Signal Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company’s lead product candidate is roluperidone, which is in Phase III clinical trial, a compound […]
Read MoreI’ve started this week by diving into stocks in the Materials sector. The market’s rally over the last week or so has been good for a number of sectors, including Materials, as economic indicators show that the U.S. remains healthy. Volatility in the oil market can wreak havoc at times with some of the stocks […]
Read More